Latest Share Chat

4D Pharma Gets Approval To Restart Thetanix Phase I Clinical Study

Fri, 10th Jun 2016 07:30

LONDON (Alliance News) - 4D Pharma PLC said Friday the UK Medicines & Healthcare Products Regulatory Agency has granted approval for 4D's phase I clinical study of Thetanix in pediatric Crohn's disease to be restarted.

The trial had been delayed as a precaution due to concerns about quality that had come to light at one of 4D's supply partners during the manufacture of an additional batch of Thetanix.

4D Pharma said that its own investigation into the matter had been completed.

Shares in 4D Pharma were up 2.6% at 880.00 pence Friday morning.

By Hana Stewart-Smith; hanassmith@alliancenews.com; @HanaSSAllNews

Related Shares

More News

15 Feb 2023 14:21

IN BRIEF: 4D Pharma shares cancelled from trading on London's AIM

4D Pharma PLC - Leeds-based pharmaceutical firm - Notes cancellation of its shares on AIM from Thursday, after it entered into administration in June ...

3 Feb 2023 15:17

TRADING UPDATES: GCP Infra hails NAV rise; Jadestone profits from oil

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

9 Jan 2023 15:58

UK shareholder meetings calendar - next 7 days

30 Dec 2022 17:21

4D Pharma seeks approval for equity fundraise to lift suspension

(Alliance News) - 4D Pharma PLC on Friday said it was seeking shareholder approval for a USD15.0 million cash raise, as it works to lift its suspensio...

16 Nov 2022 17:00

4D Pharma says trial results show Blautix eases IBS symptoms

(Alliance News) - 4D Pharma PLC said on Wednesday that its Blautix phase 2 clinical trial results showed the treatment had a positive effect on suffer...